1
|
Sýkorová A, Procházka V, Móciková H, Janíková A, Pytlík R, Belada D, Benešová K, Klener P, Ďuraš J, Smolej L, Campr V, Blahovcová P, Trněný M. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index. Neoplasma 2022; 69:1466-1473. [PMID: 36591807 DOI: 10.4149/neo_2022_221030n1064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Accepted: 11/24/2022] [Indexed: 12/31/2022]
Abstract
Burkitt lymphoma (BL) is a rare subtype of non-Hodgkin's lymphoma with an aggressive course. To refine the individual patient's prognosis, the International Prognostic Index for BL (BL-IPI) was recently developed and 4 risk factors (RF) were determined as optimal prognostic cut-off by multivariate analysis: age ≥40 years, lactate dehydrogenase >3× upper limit of normal, ECOG performance status ≥2, and central nervous system involvement. The BL-IPI distinguishes 3 prognostic groups, low (without RF), intermediate (1 RF), and high risk (2-4 RF), with significant differences in survival. The aim of the current project was to perform an external validation of the BL-IPI in 101 patients from the Registry of Czech Lymphoma Study Group diagnosed between 1999 and 2016 (median age, 45 years). The median follow-up was 50.4 months. The induction treatment included rituximab plus chemotherapy in 82% and chemotherapy alone in 18%. The overall response rate was 78% and the complete remission rate was 73%. According to BL-IPI, low/intermediate/high risk was present in 21/35/45% of patients, showing high similarity to the training BL-IPI US (United States) dataset (18/36/46%). There were significant differences in progression-free survival (PFS) and overall survival (OS) between patients with high vs. intermediate risk (PFS: hazard ratio 0.16, 95% confidence interval 0.08-0.31, p<0.0001; OS: hazard ratio 0.17, 95% confidence interval 0.09-0.35, p<0.0001) but not between patients with low vs. intermediate risk. The 3-year OS probability according to BL-IPI with low/intermediate/high risk was 96/76/59% in the BL-IPI training dataset vs. 95/85/45% in our external validation cohort; the 3-year PFS probability with low/intermediate/high risk was 92/72/53% in the BL-IPI training dataset vs. 95/85/42% in our cohort. In summary, our external validation of the BL-IPI confirmed a good separation of high-risk patients, who have a poor prognosis and for whom the new therapeutic approaches are needed; patients with low and intermediate risk had favorable clinical outcomes, and differences between these groups were not significant, likely due to a small number of patients.
Collapse
Affiliation(s)
- Alice Sýkorová
- 4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Vít Procházka
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Heidi Móciková
- Department of Clinical Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Andrea Janíková
- Department of Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - Robert Pytlík
- 1st Department of Medicine-Department of Hematology, Charles University, General Hospital, Prague, Czech Republic.,Department of Cell Therapy, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | - David Belada
- 4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Kateřina Benešová
- 1st Department of Medicine-Department of Hematology, Charles University, General Hospital, Prague, Czech Republic
| | - Pavel Klener
- 1st Department of Medicine-Department of Hematology, Charles University, General Hospital, Prague, Czech Republic
| | - Juraj Ďuraš
- Department of Hemato-Oncology, Faculty of Medicine, Ostrava, Czech Republic
| | - Lukáš Smolej
- 4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Vít Campr
- Institute of Pathology, University Hospital Motol, Prague, Czech Republic
| | - Petra Blahovcová
- Data Management Office, 1st Department of Internal Medicine-Department of Hematology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic
| | - Marek Trněný
- 1st Department of Medicine-Department of Hematology, Charles University, General Hospital, Prague, Czech Republic
| |
Collapse
|
2
|
Mocikova H, Pytlik R, Benesova K, Janikova A, Duras J, Sykorova A, Steinerova K, Prochazka V, Campr V, Belada D, Dlouha J, Trneny M. PERIPHERAL T‐CELL LYMPHOMAS INVOLVING CENTRAL NERVOUS SYSTEM: A REPORT FROM THE CZECH LYMPHOMA STUDY GROUP REGISTRY. Hematol Oncol 2021. [DOI: 10.1002/hon.132_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- H. Mocikova
- University Hospital Kralovske Vinohrady and Third Faculty of Medicine Charles University Department of Haematology Prague Czech Republic
| | - R. Pytlik
- Institute of Haematology and Blood Transfusion Cell Therapy Department Prague Czech Republic
| | - K. Benesova
- Charles University General Hospital First Department of Medicine Department of Hematology Prague Czech Republic
| | - A. Janikova
- University Hospital Brno Department of Hematology and Oncology Brno Czech Republic
| | - J. Duras
- University Hospital and Faculty of Medicine Department of Hemato‐Oncology Ostrava Czech Republic
| | - A. Sykorova
- University Hospital and Faculty of Medicine 4th Department of Internal Medicine– Hematology Hradec Kralove Czech Republic
| | - K. Steinerova
- University Hospital Department of Clinical Hematology Pilsen Czech Republic
| | - V. Prochazka
- Faculty of Medicine and Dentistry Palacky University Department of Haemato‐Oncology Olomouc Czech Republic
| | - V. Campr
- University Hospital Motol Institute of Pathology and Molecular Medicine Prague Czech Republic
| | - D. Belada
- University Hospital and Faculty of Medicine 4th Department of Internal Medicine– Hematology Hradec Kralove Czech Republic
| | - J. Dlouha
- Czech Lymphoma Study Group Registry Data Management Office Prague Czech Republic
| | - M. Trneny
- Charles University General Hospital First Department of Medicine Department of Hematology Prague Czech Republic
| |
Collapse
|
3
|
Procházka V, Belada D, Janíková A, Benešová K, Mociková H, Ďuraš J, Pirnos J, Kopečková K, Campr V, Fürst T, Pytlík R, Sýkorová A, Michalka J, Dlouhá J, Papajík T, Trněný M. Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP. EJHaem 2020; 1:170-180. [PMID: 35847728 PMCID: PMC9175682 DOI: 10.1002/jha2.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 06/30/2020] [Accepted: 07/02/2020] [Indexed: 12/03/2022]
Abstract
Twenty percent of patients with high-tumor-burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years since POD event. Rituximab maintenance was proven to reduce relapse rate in responding FL, but its role on preventing POD was not defined. We analyzed 1360 HTB-FL patients from the Czech Lymphoma Study Group registry treated with frontline rituximab-containing regimen. Of those, 950 cases received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and achieved complete or partial remission: 712 patients received rituximab maintenance (MAINT) and 238 were a historical observational cohort (OBS). We have proposed a modified POD24 (mPOD24) endpoint for the chemosensitive patients calculated from the end-of-induction (EOI). Survival rates since EOI were as follows: 5-year overall survival (OS) 86.2% versus 94.5% in the OBS and MAINT groups, respectively (P < .001) and 5-year progression-free survival 58.5% (OBS) and 75.4% (MAINT) (P < .001). The Cox proportional hazards model showed a decrease in mPOD24 incidence in the MAINT group with the overall hazard rate reduced by 56% (hazard ratio = 0.44; P < .001). The cumulative incidence of mPOD24 was reduced from 24.1% in OBS to 10.1% in MAINT (P < .001). Comparison of non-mPOD24 cases showed OS similar to that in the general population. Rituximab maintenance given after R-CHOP resulted in a 2.4-fold reduction in mPOD24 incidence. Once the non-POD24 status is achieved, FL does not shorten the patients' life expectancy.
Collapse
Affiliation(s)
- Vít Procházka
- Department of Hemato‐Oncology, Faculty of Medicine and DentistryUniversity Hospital in OlomoucOlomoucCzech Republic
| | - David Belada
- Fourth Department of Internal Medicine – HematologyUniversity HospitalHradec KrálovéCzech Republic
| | - Andrea Janíková
- Department of Hematology and OncologyMasaryk University Hospital BrnoBrnoCzech Republic
| | - Kateřina Benešová
- First Department of Internal Medicine – HematologyFirst Faculty of Medicine and General Teaching HospitalPragueCzech Republic
| | - Heidi Mociková
- Department of Internal Medicine and Hematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of MedicineCharles UniversityPragueCzech Republic
| | - Juraj Ďuraš
- Department of Hemato‐OncologyUniversity Hospital OstravaOstravaCzech Republic
| | - Jan Pirnos
- Department of OncologyHospital České BudějoviceČeské BudějoviceCzech Republic
| | | | - Vít Campr
- Department of Pathology and Molecular MedicineUniversity Hospital in MotolPragueCzech Republic
- Second Faculty of MedicineCharles UniversityPragueCzech Republic
| | - Tomáš Fürst
- Department of Mathematical Analysis and Applications of Mathematics, Faculty of SciencePalacký UniversityOlomoucCzech Republic
| | - Robert Pytlík
- First Department of Internal Medicine – HematologyFirst Faculty of Medicine and General Teaching HospitalPragueCzech Republic
| | - Alice Sýkorová
- Fourth Department of Internal Medicine – HematologyUniversity HospitalHradec KrálovéCzech Republic
| | - Jozef Michalka
- Department of Hematology and OncologyMasaryk University Hospital BrnoBrnoCzech Republic
| | - Jitka Dlouhá
- First Department of Internal Medicine – HematologyFirst Faculty of Medicine and General Teaching HospitalPragueCzech Republic
| | - Tomáš Papajík
- Department of Hemato‐Oncology, Faculty of Medicine and DentistryUniversity Hospital in OlomoucOlomoucCzech Republic
| | - Marek Trněný
- First Department of Internal Medicine – HematologyFirst Faculty of Medicine and General Teaching HospitalPragueCzech Republic
| |
Collapse
|
4
|
Abstract
Summary. Background: A histopathological examination was conducted on vein samples from six patients who had undergone great saphenous vein sealing with Histoacryl and Lipiodol to treat chronic venous insufficiency of the superficial venous system. Patients and methods: In each patient a sample of the complete vein including the surrounding tissue was obtained through a minor incision under perioperative sonographic monitoring. Each patient had signed an informed consent form. Samples were taken at the following intervals: six days, six weeks, six months, one year, two years, and three years after treatment. Results: N-butyl-2-cyanoacrylate with Lipiodol induces a thrombotic reaction in the acute phase and endothelium is destroyed but no significant inflammation or substantial vascular wall damage is present. In the subsequent period, a foreign body giant cell reaction emerges accompanied by only moderate chronic inflammation that does not extend to the vascular wall or the surrounding tissue. The thrombus is organized with minimal recanalization. The foreign material is gradually degraded, and it is no longer detectable after three years. The vessel wall showed slight sclerotization. Conclusions: N-butyl-2-cyanoacrylate that has been applied gradually degrades over the course of three years accompanied by a giant cell reaction, mild chronic inflammation and cicatrices, but there is minimal recanalization of the obturated section.
Collapse
Affiliation(s)
| | - Vít Campr
- Faculty Hospital Motol, Prague, Czechia
| |
Collapse
|
5
|
Trneny M, Polgarova K, Janikova A, Belada D, Prochazka V, Duras J, Mocikova H, Steinerova K, Campr V, Blahovcova P, Petrova M, Zogala D, Ptacnik V. IS IT RADIOTHERAPY NECESSARY FOR PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) PATIENTS ACHIEVING PET NEGATIVITY AFTER IMMUNOCHEMOTHERAPY? Hematol Oncol 2019. [DOI: 10.1002/hon.77_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Trneny
- Ist Dept Med; Charles University General Hospital; Praha Czech Republic
| | - K. Polgarova
- Ist Dept Med; Charles University General Hospital; Praha Czech Republic
| | - A. Janikova
- Dept Hemato-Oncology; University Hospital Brno; Brno Czech Republic
| | - D. Belada
- Dept Hematology; University Hospital; Hradec Kralove Czech Republic
| | - V. Prochazka
- Dept Hematology; University Hospital; Olomouc Czech Republic
| | - J. Duras
- Dept Hematology; University Hospital; Ostrava Czech Republic
| | - H. Mocikova
- Dept Hematology; University Hospital Kralovske Vinohrady; Praha Czech Republic
| | - K. Steinerova
- Dept Hematology; University Hospital; Plzen Czech Republic
| | - V. Campr
- Dept Pathology; University Hospital Motol; Praha Czech Republic
| | - P. Blahovcova
- Data Center; Czech Lymphoma Study Group; Praha Czech Republic
| | - M. Petrova
- Data Center; Czech Lymphoma Study Group; Praha Czech Republic
| | - D. Zogala
- Dept Nuclear Medicine; Charles University General Hospital; Praha Czech Republic
| | - V. Ptacnik
- Dept Nuclear Medicine; Charles University General Hospital; Praha Czech Republic
| |
Collapse
|
6
|
Janikova A, Chloupkova R, Campr V, Kopalova N, Klener P, Benesova K, Hamouzova J, Belada D, Sykorova A, Prochazka V, Pirnos J, Duras J, Mocikova H, Michalka J, Trneny M. PROGNOSTIC VALUE OF THE INTERVAL BETWEEN RELAPSE AND THERAPY INITIATION IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP DATABASE. Hematol Oncol 2019. [DOI: 10.1002/hon.83_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Janikova
- Department of Internal Medicine - Hematology nad Oncology; Masaryk University and Univesity Hospital Brno; Brno Czech Republic
| | - R. Chloupkova
- Institute of Biostatistics and Analyses; Faculty of Medicine Masaryk University Brno; Brno Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine; 2nd Faculty of Medicine, Charles University Prague and Motol University Hospital; Prague Czech Republic
| | - N. Kopalova
- Department of Internal Medicine - Hematology nad Oncology; Masaryk University and Univesity Hospital Brno; Brno Czech Republic
| | - P. Klener
- First Internal Clinic - Clinic of Hematology; General University Hospital and First Faculty of Medicine, Charles University; Prague Czech Republic
| | - K. Benesova
- First Internal Clinic - Clinic of Hematology; General University Hospital and First Faculty of Medicine, Charles University; Prague Czech Republic
| | - J. Hamouzova
- First Internal Clinic - Clinic of Hematology; General University Hospital and First Faculty of Medicine, Charles University; Prague Czech Republic
| | - D. Belada
- The 4th Department of Internal Medicine - Hematology; University Hospital and Faculty of Medicine in Hradec Králové Charles University; Hradec Kralove Czech Republic
| | - A. Sykorova
- The 4th Department of Internal Medicine - Hematology; University Hospital and Faculty of Medicine in Hradec Králové Charles University; Hradec Kralove Czech Republic
| | - V. Prochazka
- Department of Hemato-Oncology; Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - J. Pirnos
- Department of Oncology; Hospital Ceske Budejovice; Ceske Budejovice Czech Republic
| | - J. Duras
- Department of Haematooncology; University Hospital Ostrava and Medical Faculty of the Ostrava University; Ostrava Czech Republic
| | - H. Mocikova
- Internal Clinic of Haematology; University Hospital Kralovske Vinohrady Prague and Third Faculty of Medicine, Charles University Prague; Prague Czech Republic
| | - J. Michalka
- Department of Internal Medicine - Hematology nad Oncology; Masaryk University and Univesity Hospital Brno; Brno Czech Republic
| | - M. Trneny
- First Internal Clinic - Clinic of Hematology; General University Hospital and First Faculty of Medicine, Charles University; Prague Czech Republic
| |
Collapse
|
7
|
Janikova A, Chloupkova R, Klener P, Benesova K, Campr V, Belada D, Sykorova A, Prochazka V, Kopalova N, Hamouzova J, Pirnos J, Duras J, Mocikova H, Trneny M. T-CELL LYMPHOMA IN THE ELDERLY PATIENTS. WHO IS YOUNG, OLD, AND ELDERLY? Hematol Oncol 2019. [DOI: 10.1002/hon.145_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Janikova
- Department of Internal Medicine - Hematology nad Oncology; Univesity Hospital Brno; Brno Czech Republic
| | - R. Chloupkova
- Institute of Biostatistics and Analyses; Faculty of Medicine Masaryk University Brno; Brno Czech Republic
| | - P. Klener
- 1st Internal Clinic- Clinic of Hematology; First Medical Faculty, Charles University, and General University Hospital; Prague Czech Republic
| | - K. Benesova
- 1st Internal Clinic- Clinic of Hematology; First Medical Faculty, Charles University, and General University Hospital; Prague Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine; 2nd Faculty of Medicine, Charles University and Faculty Hospital in Motol; Prague Czech Republic
| | - D. Belada
- 4th Department of Internal Medicine - Hematology; Charles University, Hospital and Faculty of Medicine; Hradec Králové Hradec Kralove Czech Republic
| | - A. Sykorova
- 4th Department of Internal Medicine - Hematology; Charles University, Hospital and Faculty of Medicine; Hradec Králové Hradec Kralove Czech Republic
| | - V. Prochazka
- Department of Hemato-Oncology; University Hospital Olomouc; Olomouc Czech Republic
| | - N. Kopalova
- Department of Internal Medicine - Hematology nad Oncology; Univesity Hospital Brno; Brno Czech Republic
| | - J. Hamouzova
- 1st Internal Clinic- Clinic of Hematology; First Medical Faculty, Charles University, and General University Hospital; Prague Czech Republic
| | - J. Pirnos
- Department of Oncology; Hospital Ceske Budejovice; Ceske Budejovice Czech Republic
| | - J. Duras
- Department of Haematooncology; University Hospital Ostrava and Medical Faculty of the Ostrava University; Ostrava Czech Republic
| | - H. Mocikova
- Internal Clinic of Haematology; University Hospital Kralovske Vinohrady Prague and Third Faculty of Medicine, Charles University Prague; Prague Czech Republic
| | - M. Trneny
- 1st Internal Clinic- Clinic of Hematology; First Medical Faculty, Charles University, and General University Hospital; Prague Czech Republic
| |
Collapse
|
8
|
Škába R, Hoch J, Jech Z, Kynčl M, Campr V. [Hirschsprungs disease in adults two case reports and review of the literature]. Rozhl Chir 2018; 97:133-138. [PMID: 29589457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Hirschsprungs disease (HD) in adults is extremely rare, only three publications in Czech and Czechoslovak journals making reference to the condition after childhood. We present two cases of adult patients with HD. The first case is a 46-year-old male patient suffering from chronic constipation since childhood and diagnosed with megacolon at the age of 16; however, no further detailed diagnosis was done. At the age of 41, he developed a sigmoid perforation due to fecaloma and underwent urgent rectosigmoid resection and colostomy. 5 months later, Swensons coloanal anastomosis with diverting ileostomy was performed. Postoperative course was uneventful. He has two bowel movements a day. 7 years after the Swensons procedure, he also underwent adhesiolysis for acute bowel obstruction. His daughter was operated on due to HD at 16 days of age. The second case is a 57-year-old male patient. He suffered from chronic constipation and megacolon since 2 years of age and was diagnosed with congenital megacolon at the age of 19. However, no detailed diagnostics followed. He had a long interval between stools of up to 14 days. He underwent colonoscopy and, with a diagnosis of resistant Crohns disease, was referred to a surgical department where he was diagnosed with HD. Left hemicolectomy was first performed, followed by Swensons procedure with diverting ileostomy. All postoperative courses were uneventful. Currently he passes one or two soft stools a day. Adult HD is extremely rare. However, adult surgeons should consider it in case of refractory constipation since childhood associated with megacolon. Diagnosis is based on contrast radiography and rectal biopsy. Both Swensons and Duhamels procedures are suitable for surgical management. Left hemicolectomy with colonic rotation and coloanal anastomosis and/or proctocolectomy with J-pouch anastomosis are indicated in advanced forms of non-functional megacolon.Key words: adult Hirschsprungs disease - megacolon surgical therapy.
Collapse
|
9
|
Bartoňová L, Campr V, Chmelová R, Taudy M, Kodet R. Nonfunctioning parathyroid carcinoma associated with parathyromatosis. A case report. Cesk Patol 2018; 54:37-42. [PMID: 29631411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
We report on the case of a 39-year old man who underwent a thyroidectomy and a parathyroidectomy with misdiagnosed medullary carcinoma of the thyroid in 2013. During the operation the thyroid gland and parathyroid glands were artificially damaged due to the complicated surgical access to the glands because of the obesity of the patient as well as the deep placement of the enlarged parathyroid glands. Three years later, the neck ultrasound showed bilateral nodules on the neck, suspected to be metastases of the medullary carcinoma. Microscopically, the nodules were found to be focuses of parathyromatosis, and there was also an infiltrating carcinoma. This lesion was reclassified after clinico-pathological correlation and immunohistochemical examination as nonfunctioning parathyroid carcinoma. This article discusses morphological and immunohistochemical features of parathyromatosis and parathyroid carcinoma and its separation from lesions with which it may be misdiagnosed.
Collapse
|
10
|
Sýkorová A, Pytlík R, Móciková H, Janíková A, Procházka V, Belada D, Šálek D, Benešová K, Klener P, Ďuraš J, Smolej L, Šimkovič M, Campr V, Vosáhlová V, Blahovcová P, Trněný M. Burkitt lymphoma-multicenter retrospective data analysis from the Czech Lymphoma Study Group-NiHiL project. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_90] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Sýkorová
- 4th Department of Internal Medicine-Hematology; University Hospital and Faculty of Medicine; Hradec Kralove Czech Republic
| | - R. Pytlík
- 1st Department of Medicine-Department of Hematology; Charles University, General Hospital; Prague Czech Republic
| | - H. Móciková
- Department of Clinical Hematology; University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University; Prague Czech Republic
| | - A. Janíková
- Department of Hematology and Oncology; University Hospital; Brno Czech Republic
| | - V. Procházka
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| | - D. Belada
- 4th Department of Internal Medicine-Hematology; University Hospital and Faculty of Medicine; Hradec Kralove Czech Republic
| | - D. Šálek
- Department of Hematology and Oncology; University Hospital; Brno Czech Republic
| | - K. Benešová
- 1st Department of Medicine-Department of Hematology; Charles University, General Hospital; Prague Czech Republic
| | - P. Klener
- 1st Department of Medicine-Department of Hematology; Charles University, General Hospital; Prague Czech Republic
| | - J. Ďuraš
- Department of Hemato-Oncology; Faculty of Medicine; Ostrava Czech Republic
| | - L. Smolej
- 4th Department of Internal Medicine-Hematology; University Hospital and Faculty of Medicine; Hradec Kralove Czech Republic
| | - M. Šimkovič
- 4th Department of Internal Medicine-Hematology; University Hospital and Faculty of Medicine; Hradec Kralove Czech Republic
| | - V. Campr
- Institute of Pathology; University Hospital Motol; Prague Czech Republic
| | - V. Vosáhlová
- 4th Department of Internal Medicine-Hematology; University Hospital and Faculty of Medicine; Hradec Kralove Czech Republic
| | - P. Blahovcová
- Data Management Office, 1st Department of Medicine-Department of Hematology; Charles University, General Hospital; Prague Czech Republic
| | - M. Trněný
- 1st Department of Medicine-Department of Hematology; Charles University, General Hospital; Prague Czech Republic
| |
Collapse
|
11
|
Trneny M, Campr V, Pytlik R, Klener P, Stritesky J, Jaksa R, Boudova L, Benesova K, Koren J, Trnkova M, Blahovcova P, Klanova M. DOUBLE-EXPRESSOR LYMPHOMAS DO NOT HAVE INFERIOR OUTCOME AFTER AUTOLOGOUS STEM-CELL TRANSPLANT IN THE FIRST LINE TREATMENT. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Trneny
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - V. Campr
- Dept Pathology; University Hospital Motol; Praha Czech Republic
| | - R. Pytlik
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - P. Klener
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - J. Stritesky
- Department of Pathology; Charles University General Hospital; Prague 2 Czech Republic
| | - R. Jaksa
- Department of Pathology; Charles University General Hospital; Prague 2 Czech Republic
| | - L. Boudova
- Department of Pathology; University Hospital Plzen; Plzen Czech Republic
| | - K. Benesova
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - J. Koren
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - M. Trnkova
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - P. Blahovcova
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - M. Klanova
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| |
Collapse
|
12
|
Obr A, Klener P, Belada D, Pytlik R, Simkovic M, Salek D, Mocikova H, Prochazka V, Janikova A, Markova J, Campr V, Kodet R, Trneny M. MAINTENANCE RITUXIMAB IMPROVES SURVIVAL IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: ANALYSIS OF THE CZECH LYMPHOMA STUDY GROUP. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_69] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Obr
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - P. Klener
- First Medical Dept.; Charles University General Hospital in Prague; Prague 1 Czech Republic
| | - D. Belada
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - R. Pytlik
- First Medical Dept.; Charles University General Hospital in Prague; Prague 1 Czech Republic
| | - M. Simkovic
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - D. Salek
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - H. Mocikova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Prague 10 Czech Republic
| | - V. Prochazka
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - A. Janikova
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - J. Markova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Prague 10 Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine; Charles University Hospital in Motol, Prague, and Second Faculty of Medicine; Praha 5 Czech Republic
| | - R. Kodet
- Department of Pathology and Molecular Medicine; Charles University Hospital in Motol, Prague, and Second Faculty of Medicine; Praha 5 Czech Republic
| | - M. Trneny
- First Medical Dept.; Charles University General Hospital in Prague; Prague 1 Czech Republic
| |
Collapse
|
13
|
Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcová P, Janikova A, Markova J, Obr A, Berkova A, Vaskova M, Mejstrikova E, Campr V, Kubinyi J, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M. R-CHOP/R-HDAC AND RITUXIMAB MAINTENANCE RESULTS IN HIGH COMPLETE REMISSION RATE, MINIMAL RESIDUAL DISEASE NEGATIVITY, AND EXCELLENT SURVIVAL IN ELDERLY MCL PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Klener
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - E. Fronkova
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - D. Belada
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - K. Forsterova
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - R. Pytlik
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - M. Kalinova
- Institute of Pathology and Molecular Medicine; Charles University Hospital in Motol and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - M. Simkovic
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - D. Salek
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - H. Mocikova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - V. Prochazka
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - P. Blahovcová
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - A. Janikova
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - J. Markova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - A. Obr
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - A. Berkova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - M. Vaskova
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - E. Mejstrikova
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - V. Campr
- Institute of Pathology and Molecular Medicine; Charles University Hospital in Motol and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - J. Kubinyi
- Institute of nuclear medicine; Charles University General Hospital in Prague; Prague Czech Republic
| | - R. Jaksa
- Institute of Pathology; Charles University Hospital and First Faculty of Medicine, Prague; Prague Czech Republic
| | - R. Kodet
- Institute of Pathology and Molecular Medicine; Charles University Hospital in Motol and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - K. Michalova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - J. Trka
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - M. Trneny
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| |
Collapse
|
14
|
Janikova A, Campr V, Kopalova N, Benesova K, Belada D, Prochazka V, Duras J, Dlouha J, Mocikova H, Sykorova A, Brejcha M, Mayer J, Trneny M. Beyond rituximab maintenance. relapsing follicular lymphoma during or after end of rituximab maintenance: analysis of Czech Lymphoma Study Group (CLSG) database. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_117] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Janikova
- Department of Hematology and Oncology, Faculty of Medicine; Masaryk University and University Hospital Brno; Brno Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine; Charles University and Faculty Hospital in Motol, Prague; Prague Czech Republic
| | - N. Kopalova
- Department of Hematology and Oncology, Faculty of Medicine; Masaryk University and University Hospital Brno; Brno Czech Republic
| | - K. Benesova
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| | - D. Belada
- 4th Department of Internal medicine-Hematology; Charles University Hospital and Faculty of Medicine, Hradec Králové; Hradec Kralove Czech Republic
| | - V. Prochazka
- Department of Hematology; University Hospital Olomouc; Olomouc Czech Republic
| | - J. Duras
- Department of Clinical Hematology; Teaching Hospital Ostrava; Ostrava Czech Republic
| | - J. Dlouha
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| | - H. Mocikova
- Internal Clinic of Haematology; University Hospital Kralovske Vinohrady and Charles University, 3rd Faculty of Medicine, Prague; Prague Czech Republic
| | - A. Sykorova
- 4th Department of Internal medicine-Hematology; Charles University Hospital and Faculty of Medicine, Hradec Králové; Hradec Kralove Czech Republic
| | - M. Brejcha
- Department of Hematology; Hospital Novy Jicin; Novy Jicin Czech Republic
| | - J. Mayer
- Department of Hematology and Oncology, Faculty of Medicine; Masaryk University and University Hospital Brno; Brno Czech Republic
| | - M. Trneny
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| |
Collapse
|
15
|
Janikova A, Campr V, Kopalova N, Benesova K, Belada D, Dlouha J, Duras J, Prochazka V, Mocikova H, Kubackova K, Sykorova A, Brejcha M, Mayer J, Trneny M. INCIDENCE AND OUTCOME OF PRIMARY EXTRANODAL FOLLICULAR LYMPHOMAS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) REGISTRY. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Janikova
- Hematology and Oncology; University Hospital Brno; Brno Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine; Charles University and Faculty Hospital in Motol; Prague Czech Republic
| | - N. Kopalova
- Hematology and Oncology; University Hospital Brno; Brno Czech Republic
| | - K. Benesova
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| | - D. Belada
- 4th Department of Internal medicine - Hematology; Charles University Hospital and Faculty of Medicine, Hradec Králové; Hradec Kralove Czech Republic
| | - J. Dlouha
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| | - J. Duras
- Department of Clinical Hematology; Teaching Hospital Ostrava; Ostrava Czech Republic
| | - V. Prochazka
- Department of Hematology; University Hospital Olomouc; Olomouc Czech Republic
| | - H. Mocikova
- Internal Clinic of Haematology; University Hospital Kralovske Vinohrady and Charles University, 3rd Faculty of Medicine Prague; Prague Czech Republic
| | - K. Kubackova
- Department of Oncology, 2nd Faculty of Medicine; Charles University and Faculty Hospital in Motol, Prague; Prague Czech Republic
| | - A. Sykorova
- 4th Department of Internal medicine - Hematology; Charles University Hospital and Faculty of Medicine, Hradec Králové; Hradec Kralove Czech Republic
| | - M. Brejcha
- Department of Hematology; Hospital Novy Jicin; Novy Jicin Czech Republic
| | - J. Mayer
- Hematology and Oncology; University Hospital Brno; Brno Czech Republic
| | - M. Trneny
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| |
Collapse
|
16
|
Klener P, Salek D, Mocikova H, Blahovcova P, Pytlik R, Janikova A, Prochazka V, Campr V, Boudova L, Jaksa R, Kodet R, Trneny M. RITUXIMAB MAINTENANCE AFTER NORDIC PROTOCOL (R-MAXICHOP/HD-ARAC/ASCT) SIGNIFICANTLY PROLONGS SURVIVAL IN YOUNG MANTLE CELL LYMPHOMA PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Klener
- First Dept. of Internal Medicine; Charles University General Hospital and First Faculty of Medicine; Prague Czech Republic
| | - D. Salek
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - H. Mocikova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - P. Blahovcova
- First Dept. of Internal Medicine; Charles University General Hospital and First Faculty of Medicine; Prague Czech Republic
| | - R. Pytlik
- First Dept. of Internal Medicine; Charles University General Hospital and First Faculty of Medicine; Prague Czech Republic
| | - A. Janikova
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - V. Prochazka
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - V. Campr
- Dept. of Pathology and Molecular Medicine; Charles University Hospital in Motol, and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - L. Boudova
- Biopticka laborator, Biopticka laborator s.r.o; Plzen Czech Republic
| | - R. Jaksa
- Institute of Pathology; Charles University General Hospital and First Faculty of Medicine, Prague; Prague Czech Republic
| | - R. Kodet
- Institute of Pathology; Charles University General Hospital and First Faculty of Medicine, Prague; Prague Czech Republic
| | - M. Trneny
- First Dept. of Internal Medicine; Charles University General Hospital and First Faculty of Medicine; Prague Czech Republic
| |
Collapse
|
17
|
Benesova K, Janikova A, Belada D, Prochazka V, Pytlik R, Mocikova H, Sykorova A, Campr V, Blahovcova P, Trneny M. SIMULTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT THE DIAGNOSIS HAS SIMILAR OUTCOME AS DLBCL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- K. Benesova
- 1st Department of Internal Medicine-Department of Hematology; First Faculty of Medicine and General Teaching Hospital; Prague Czech Republic
| | - A. Janikova
- Department of Hematology and Oncology; University Hospital Brno; Brno Czech Republic
| | - D. Belada
- 4th Department of Internal Medicine-Hematology; University Hospital and Faculty of Medicine; Hradec Kralove Czech Republic
| | - V. Prochazka
- Department of Hemato-Oncology; Faculty of Medicine and Dentistry; Olomouc Czech Republic
| | - R. Pytlik
- 1st Department of Internal Medicine-Department of Hematology; First Faculty of Medicine and General Teaching Hospital; Prague Czech Republic
| | - H. Mocikova
- Department of Clinical Hematology; University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine; Prague 10 Czech Republic
| | - A. Sykorova
- 4th Department of Internal Medicine-Hematology; University Hospital and Faculty of Medicine; Hradec Kralove Czech Republic
| | - V. Campr
- Institute of Pathology; University Hospital Motol; Prague 5 Czech Republic
| | - P. Blahovcova
- 1st Department of Internal Medicine-Department of Hematology; First Faculty of Medicine and General Teaching Hospital; Prague Czech Republic
| | - M. Trneny
- 1st Department of Internal Medicine-Department of Hematology; First Faculty of Medicine and General Teaching Hospital; Prague Czech Republic
| |
Collapse
|
18
|
Sýkorová A, Pytlík R, Móciková H, Belada D, Benešová K, Papajík T, Janíková A, Šálek D, Procházka V, Vokurka S, Campr V, Klener P, Kubáčková K, Trněný M. [Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)]. Klin Onkol 2017; 29:295-302. [PMID: 27534788 DOI: 10.14735/amko2016295] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Recent advances in the use of the imaging modalities, especially PET/CT, and their utilization for determining clinical stage (CS) and assessment treatment response (TR) in malignant lymphomas, along with development of prognostic tools and new treatment modalities, formed the basis for the revised criteria for evaluating CS and TR (published as the Lugano classification, 2014). MATERIALS AND METHODS The authors summarize the new Lugano recommendations (published in 2014) and the changes from the criteria published in 2007. Moreover, discussion of the changes places emphasis on practical use. The practicality of the Lugano classification, 2014 was the subject of consensus meeting at the annual meeting of the Cooperative Lymphoma Study Group (CLSG) in March 2015. This study reports the final consensus. The CLSG recommends use of the Lugano classification, 2014, but recommends some modifications. CONCLUSIONS Standardization of the criteria used to determine CS and TR in malignant lymphomas has led to improvements in initial staging and assessment of TR. The criteria are helpful for unifying response assessment in clinical trials and simplify the work of regulatory agencies (e.g., the EMA and the Czech State Institute for Drug Control) when registering new drugs. It also allows evaluation of treatment outcomes outside clinical trials, for example within the CLSG prospective registry of patients with newly diagnosed lymphoma. KEY WORDS malignant lymphoma - computed tomography - positron emission tomography - staging - treatment responseThis work was supported by the grant Prvouk P27/2012 of the Third Faculty of Medicine, Charles University in Prague and by the grant of the Czech Lymphoma Study Group No. NT12193-5/2011.The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 24. 1. 2016Accepted: 16. 2. 2016.
Collapse
|
19
|
Procházka V, Papajík T, Janíková A, Belada D, Kozák T, Šálek D, Sýkorová A, Móciková H, Campr V, Dlouhá J, Langová K, Fürst T, Trněný M. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database. Leuk Lymphoma 2016; 58:601-613. [DOI: 10.1080/10428194.2016.1213834] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Vít Procházka
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Tomáš Papajík
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Andrea Janíková
- Department of Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - David Belada
- 4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Tomáš Kozák
- Department of Clinical Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - David Šálek
- Department of Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - Alice Sýkorová
- 4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Heidi Móciková
- Department of Clinical Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Vít Campr
- Institute of Pathology, University Hospital Motol, Prague, Czech Republic
| | - Jitka Dlouhá
- Data Management Office, 1st Department of Internal Medicine – Department of Hematology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic
| | - Kateřina Langová
- Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Tomáš Fürst
- Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science, Palacký University, Olomouc, Czech Republic
| | - Marek Trněný
- 1st Department of Internal Medicine – Department of Hematology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic
| |
Collapse
|
20
|
Nováková M, Žaliová M, Suková M, Wlodarski M, Janda A, Froňková E, Campr V, Lejhancová K, Zapletal O, Pospíšilová D, Černá Z, Kuhn T, Švec P, Pelková V, Zemanová Z, Kerndrup G, van den Heuvel-Eibrink M, van der Velden V, Niemeyer C, Kalina T, Trka J, Starý J, Hrušák O, Mejstříková E. Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome. Haematologica 2016; 101:707-16. [PMID: 27013649 DOI: 10.3324/haematol.2015.137711] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Accepted: 03/18/2016] [Indexed: 11/09/2022] Open
Abstract
GATA-2 deficiency was recently described as common cause of overlapping syndromes of immunodeficiency, lymphedema, familiar myelodysplastic syndrome or acute myeloid leukemia. The aim of our study was to analyze bone marrow and peripheral blood samples of children with myelodysplastic syndrome or aplastic anemia to define prevalence of the GATA2 mutation and to assess whether mutations in GATA-2 transcription factor exhibit specific immunophenotypic features. The prevalence of a GATA2 mutation in a consecutively diagnosed cohort of children was 14% in advanced forms of myelodysplastic syndrome (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and myelodysplasia-related acute myeloid leukemia), 17% in refractory cytopenia of childhood, and 0% in aplastic anemia. In GATA-2-deficient cases, we found the most profound B-cell lymphopenia, including its progenitors in blood and bone marrow, which correlated with significantly diminished intronRSS-Kde recombination excision circles in comparison to other myelodysplastic syndrome/aplastic anemia cases. The other typical features of GATA-2 deficiency (monocytopenia and natural killer cell lymphopenia) were less discriminative. In conclusion, we suggest screening for GATA2 mutations in pediatric myelodysplastic syndrome, preferentially in patients with impaired B-cell homeostasis in bone marrow and peripheral blood (low number of progenitors, intronRSS-Kde recombination excision circles and naïve cells).
Collapse
Affiliation(s)
- Michaela Nováková
- CLIP-Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Markéta Žaliová
- CLIP-Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Martina Suková
- Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Marcin Wlodarski
- Center for Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
| | - Aleš Janda
- Center for Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
| | - Eva Froňková
- CLIP-Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Vít Campr
- Department of Pathology and Molecular Medicine, University Hospital Motol, Prague, Czech Republic
| | - Kateřina Lejhancová
- Department of Pediatrics, Charles University, University Hospital Hradec Králové, Czech Republic
| | - Ondřej Zapletal
- Department of Pediatric Hematology, Children's University Hospital, Brno, Czech Republic
| | - Dagmar Pospíšilová
- Department of Pediatrics, Palacky University and University Hospital Olomouc, Czech Republic
| | - Zdeňka Černá
- Department of Pediatrics, University Hospital Pilsen, Czech Republic
| | - Tomáš Kuhn
- Department of Pediatrics Ostrava, University Hospital Ostrava, Czech Republic
| | - Peter Švec
- Department of Pediatric Hematology and Oncology, University Hospital Bratislava, Slovakia
| | - Vendula Pelková
- CLIP-Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Zuzana Zemanová
- Centre of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, 1 Faculty of Medicine and General University Hospital and Charles University, Prague, Czech Republic
| | - Gitte Kerndrup
- Department of Pathology, Aarhus University Hospital, Denmark
| | | | | | - Charlotte Niemeyer
- Center for Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
| | - Tomáš Kalina
- CLIP-Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Jan Trka
- CLIP-Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Jan Starý
- Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Ondřej Hrušák
- CLIP-Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Ester Mejstříková
- CLIP-Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic Department of Pediatric Hematology and Oncology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| |
Collapse
|
21
|
Schwarz J, Ovesná P, Černá O, Kissová J, Soukupová JM, Brychtová Y, Doubek M, Červinek L, Cmunt E, Dulíček P, Campr V, Křen L, Penka M. Thrombosis in thrombocythemic Ph‐ myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. Eur J Haematol 2015; 96:98-106. [DOI: 10.1111/ejh.12554] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/20/2015] [Indexed: 02/02/2023]
Affiliation(s)
- Jiří Schwarz
- Institute of Hematology and Blood Transfusion Prague Czech Republic
- Institute of Clinical and Experimental Hematology 1st Medical Faculty Charles University Prague Czech Republic
| | - Petra Ovesná
- Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
| | - Olga Černá
- Internal Hematology Clinic Faculty Hospital Královské Vinohrady Prague Czech Republic
| | - Jarmila Kissová
- Department of Clinical Hematology Faculty Hospital Brno Masaryk University Brno Czech Republic
| | | | - Yvona Brychtová
- Department of Internal Medicine – Hematology and Oncology Faculty Hospital Brno Masaryk University Brno Czech Republic
| | - Michael Doubek
- Department of Internal Medicine – Hematology and Oncology Faculty Hospital Brno Masaryk University Brno Czech Republic
| | - Libor Červinek
- Department of Internal Medicine – Hematology and Oncology Faculty Hospital Brno Masaryk University Brno Czech Republic
| | - Eduard Cmunt
- Department of Clinical Hematology of the 1st Department of Internal Medicine 1st Medical Faculty Charles University Prague Czech Republic
| | - Petr Dulíček
- 4th Department of Internal Medicine – Hematology Faculty Hospital Charles University Hradec Králové Czech Republic
| | - Vít Campr
- Institute of Hematology and Blood Transfusion Prague Czech Republic
- Institute of Pathological Anatomy 2nd Medical Faculty Faculty Hospital Motol Charles University Prague Czech Republic
| | - Leoš Křen
- Department of Pathology Faculty Hospital Brno Masaryk University Brno Czech Republic
| | - Miroslav Penka
- Department of Clinical Hematology Faculty Hospital Brno Masaryk University Brno Czech Republic
| | | |
Collapse
|
22
|
Campr V, Stritesky J, Neuwirtova R, Fuchs O, Jonasova A. 232 THE SIGNIFICANCE OF TRANSCRIPTION FACTORS FLI1 AND P53 FOR THE EFFECTIVE MEGAKARYOPOIESIS STUDIED IMMUNOHISTOCHEMICALLY IN 5Q- SYNDROME AND THE EFFECT OF LENALIDOMIDE TREATMENT. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30233-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Procházka V, Pytlík R, Janíková A, Belada D, Šálek D, Papajík T, Campr V, Fürst T, Furstova J, Trněný M. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. PLoS One 2014; 9:e102594. [PMID: 25058337 PMCID: PMC4109941 DOI: 10.1371/journal.pone.0102594] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Accepted: 06/20/2014] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) have been documented as independent predictors of survival in patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL). Analysis of the prognostic impact of ALC and AMC in the context of International Prognostic Index (IPI) and other significant variables in elderly population treated in the R-CHOP regime has not been carried out yet. METHODOLOGY/PRINCIPAL FINDINGS In this retrospective study, a cohort of 443 newly diagnosed DLBCL patients with age ≥ 60 was analyzed. All patients were treated with the R-CHOP therapy. An extensive statistical analysis was performed to identify risk factors of 3-year overall survival (OS). In multivariate analysis, only three predictors proved significant: Eastern Cooperative Oncology Group performance status (ECOG), age and bulky disease presence. These predictors were dichotomized (ECOG ≥ 1, age ≥ 70, bulk ≥ 7.5) to create a novel four-level score. This score predicted 3-year OS of 94.0%, 77.4%, 62.7% and 35.4% in the low-, low-intermediate, high-intermediate and high-risk groups, respectively (P<0.001). Further, a three-level score was tested which stratifies the population better (3-year OS: 91.9%, 67.2%, 36.2% in the low, intermediate and high-risk groups, respectively) but is more difficult to interpret. Both the 3- and 4-level scores were compared to standard scoring systems and, in our population, were shown to be superior in terms of patients risk stratification with respect to 3-year OS prediction. The results were successfully validated on an independent cohort of 162 patients of similar group characteristics. CONCLUSIONS The prognostic role of baseline ALC, AMC or their ratio (LMR) was not confirmed in the multivariate context in elderly population with DLBCL treated with R-CHOP. The newly proposed age-specific index stratifies the elderly population into risk groups more precisely than the conventional IPI and its existing variants.
Collapse
MESH Headings
- Age Factors
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Biomarkers/analysis
- Cyclophosphamide/administration & dosage
- Doxorubicin/administration & dosage
- Female
- Humans
- Leukocyte Count
- Lymphocytes/pathology
- Lymphoma, Large B-Cell, Diffuse/diagnosis
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Middle Aged
- Monocytes/pathology
- Prednisone/administration & dosage
- Prognosis
- Research Design/statistics & numerical data
- Retrospective Studies
- Risk Factors
- Rituximab
- Survival Analysis
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- Vít Procházka
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
| | - Robert Pytlík
- First Internal Department, Charles University General Hospital, Prague, Czech Republic
| | - Andrea Janíková
- Department of Internal Medicine-Hematooncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - David Belada
- Second Department of Medicine, Department of Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
| | - David Šálek
- Department of Internal Medicine-Hematooncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - Tomáš Papajík
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
| | - Vít Campr
- Department of Pathology and Molecular Medicine, Charles University, and Second Medical School and Faculty Hospital in Motol, Prague, Czech Republic
| | - Tomáš Fürst
- Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science, Palacký University, Olomouc, Czech Republic
| | - Jana Furstova
- Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science, Palacký University, Olomouc, Czech Republic
- * E-mail:
| | - Marek Trněný
- First Internal Department, Charles University General Hospital, Prague, Czech Republic
| |
Collapse
|
24
|
Krsková L, Mrhalová M, Kalinová M, Campr V, Capková L, Grega M, Háček J, Hornofová L, Chadimová M, Chmelová R, Kodetová D, Zámečník J, Kodet R. [Soft tissue tumors - the view of the molecular biologist]. Cesk Patol 2014; 50:132-140. [PMID: 25186594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Soft tissue tumors (SSTs) constitute a broad spectrum of neoplasms with diverse biological properties. Rare or unusual types are often difficult to classify. Recent studies show, that a significant subset of SSTs including many types of sarcomas are associated with specific genetic changes such as chromosomal translocations producing chimeric genes, which play a role in the pathogenesis of SSTs. Because SSTs represent a diagnostically challenging group of tumors, molecular-genetic techniques (FISH or PCR) are useful as supplementary and/or confirmatory diagnostic tools. In the present paper we demonstrate the usefulness of a combined diagnostic approach using the tools of classical histopathology and immunohistochemistry together with the molecular diagnostic approach in selected nosologic entites.
Collapse
|
25
|
Kalinová M, Mrhalová M, Krsková L, Jungbauerová H, Kalfusová A, Manďáková P, Candová J, Soukup J, Campr V, Kodet R. [A complex diagnostic approach in lymphomas: practical aspect in short case reports]. Cesk Patol 2014; 50:118-126. [PMID: 25186592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Complex laboratory investigation is necessary for the diagnosis and relevant classification of lymphomas. The classical histopathological morphology and cytology investigation is essential, but further investigations such as immunohistochemistry and fluorescence in situ hybridization are necessary. It is also important to employ flow cytometry as a method of investigation running synchronously or preceding the histopathological approach. Last but not least, the investigation of nucleic acids in lymphoma by molecular approaches is necessary and has become an everyday practice. Communication between pathologists and clinical colleagues (oncologists, hematologists, internal medicine specialists and radiologists) is very important. We demonstrate the necessity of a complex diagnostic approach to lymphomas and an appropriate interpretation of all laboratory investigations giving examples of eight patients with various types of lymphomas. In some cases, it is impossible to properly diagnose a lymphoma without molecular investigation. Occasionally, the results of the molecular investigation may be misleading and/or may be inaccurately interpreted, leading to an incorrect conclusion. For that reason, it is very important to incorporate all specialized laboratories and their teams under one roof (preferably that of pathology departments), enabling tight and daily cooperation between the specialists. This is the way to reach a precise diagnosis in a majority of cases, as well as how to comply with clinical expectations of properly classified lymphomas for a targeted therapy of patients.
Collapse
|
26
|
Pytlík R, Belada D, Kubáčková K, Vášová I, Kozák T, Pirnos J, Bolomská I, Matuška M, Přibylová J, Campr V, Burešová L, Sýkorová A, Berková A, Klener P, Trněný M. Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial. Leuk Lymphoma 2014; 56:57-64. [PMID: 24628294 DOI: 10.3109/10428194.2014.904509] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
We have studied the feasibility and efficacy of intensified R-MegaCHOP-ESHAP-BEAM therapy in high-risk aggressive B-cell lymphomas. Altogether 105 patients (19-64 years) with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBL) or follicular lymphoma grade 3 (FL3) with an age-adjusted International Prognostic Index of 2-3 were recruited. Treatment consisted of three cycles of high-dose R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), followed by three cycles of R-ESHAP (rituximab, etoposide, methylprednisolone, cytarabine, cisplatin) and high-dose consolidation with BEAM (BCNU, etoposide, cytarabine, melphalan) and autologous stem cell transplant. The 5-year progression-free survival (PFS) was 72% (DLBCL 60%, PMBL 89%) and overall survival (OS) was 74% (DLBCL 61%, PMBL 89%) after a median follow-up of 85 months. However, an independent prognostic factor was age only, with patients ≤ 45 years having 5-year PFS 90% and patients > 45 years having PFS 54%. PMBL had better prognosis than DLBCL/FL3 in patients > 45 years (PFS, 88% vs. 48%), but not in younger patients (PFS, 91% vs. 94%).
Collapse
Affiliation(s)
- Robert Pytlík
- First Department of Medicine, General University Hospital and First Medical Faculty, Charles University , Prague , Czech Republic
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Sýkorová A, Campr V, Kašparová P, Kočová E, Belada D, Trněný M, Zák P. [Lymphomatoid granulomatosis - the past and present]. Vnitr Lek 2014; 60:225-238. [PMID: 24981698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND Lymphomatoid granulomatosis (LyG) is a rare multisystemic angiocentric and angiodestructive B lymphoproliferative disease that was first described by Liebow in 1972. Disease was then in the "gray zone" between vasculitis and lymphoproliferative disease. LyG is currently categorized as a primary B lymphoproliferative disease associated with Epstein-Barr (EB) virus according to the World Health Organization (WHO) classification of tumours. EPIDEMIOLOGY, CLINICAL COURSE AND TREATMENT: Lymphomatoid granulomatosis is a rare disease with unknown prevalence. It occurs more often in males (male : female ratio 2 : 1) between the 5th to 6th decade of life and is more frequent in Europe than in Asia. Lungs are typically the predominantly affected organ; the disease spreads predominantly by extralymphatic manner. Spleen and lymph nodes are affected at an advanced stage. The clinical features are often nonspecific. Dyspnea, cough, hemoptysis, chest pain are the most common features with/without B symptoms (fever, night sweats, weight loss) in the pulmonary involvement. The radiographic finding of the lung is very diverse, but when there are multiple bilateral nodular lesions with basal predominance in perilymphatic distribution, we should think of this disease, although LyG rarely occurs. The histopathologic examination of affected tissue (most commonly the lung) is necessary to confirm the diagnosis. The thoracoscopy is used mainly. When the pulmonary findings are without any response to antibiotics, the autoimmune cause and other granulomatous inflammations (tuberculosis, sarcoidosis, etc.) are excluded, this diagnostic performance is indicated. Prognosis is variable - from spontaneous remission to progressive disease, often with aggressive behavior. Median survival is 14 months from diagnosis and mortality rate is 60% in the first year - despite the treatment. Treatment strategy is chosen depending on the histological grade. The therapy is not yet standardized. Interferon α, rituximab, glucocorticoids, cyclophosphamide and combined immunochemotherapy have been used for the treatment. The disease may lead to pulmonary failure, fatal CNS (central nervous system) involvement and sometimes develops into progressive EB virus positive lymphoproliferative disorder. CONCLUSION Improvements in understanding of the biology of LyG, especially in determining the precise role of EB virus infection in its pathogenesis may lead to optimization of treatment strategies for this disease. Novel treatment modalities are urgently needed due to unfavourable prognosis. Adoptive immunotherapy appeals to be a promising approach.
Collapse
|
28
|
Benesova K, Forsterova K, Votavova H, Campr V, Stritesky J, Velenska Z, Prochazka B, Pytlik R, Trneny M. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Neoplasma 2013; 60:68-73. [PMID: 23067219 DOI: 10.4149/neo_2013_010] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Diffuse large B-cell lymphoma (DLBCL) consists of at least two biologically and pathogenetically different subtypes, the germinal centre B-cell (GCB) and the activated B cell type (ABC). It has been suggested that immunohistochemistry can discriminate these subtypes as well. The aim of this study was to verify the validity of the most commonly used Hans algorithm in patients with DLBCL treated with anthracycline- based chemotherapy with rituximab. Immunohistochemical staining using standard protocols was performed on formalin fixed paraffin-embedded tissues. CD20, CD5, CD23, BCL2, CD10, BCL6, MUM1 and Ki67 antibodies were applied. Out of 120 examined cases 52 patients were evaluated as GCB type and 68 patients as having non-GCB, out of a set of 99 patients treated with immunochemotherapy 45 patients with GCB and 54 patients with non-GCB DLBCL were identified. In this set of patients, there was no statistically significant difference neither in overall survival (OS) (HR 1.47 95% CI 0.51-2.63; p=0.45) nor in progression free survival (PFS) (HR 1.57, 95 % CI 0.76-3.22; p=0.731) between both groups.
Collapse
Affiliation(s)
- K Benesova
- 1st Department of Medicine, Charles University, Prague
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Kamarádová K, Campr V, Kalinová M. [What it your diagnosis? Cutaneous lymphoid hyperplasia]. Cesk Patol 2012; 48:207-208. [PMID: 24044129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|
30
|
Kodet R, Campr V, Kalinová M, Kamarádová K, Mrhalová M, Soukup J. [Histiocytic necrotizing lymphadenitis / Kikuchi-Fujimoto disease (HNL/K-F) and its differential diagnosis: analysis of 19 patients]. Cesk Patol 2012; 48:198-206. [PMID: 23121029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Histiocytic necrotizing lymphadenitis / Kikuchi-Fujimoto disease (HNL/K-F) is being recognized with an increasing frequency not only in the East Asia but also on the American continents and in the Europe. Still the diagnostics of HNL/K-F is not easy and difficulties with its proper classification persist. In a group of 19 patients diagnosed primarily or as consults at our department there were 12 woman and 7 men. An average age at diagnosis was 28 years, median 25 years. Cervical lymph nodes were involved in 18 patients. Bilateral lymphadenopathy was present in one patient, the remaining 17 were unilateral. Inguinal lymph node was affected in one patient. In one other patient there were enlarged retroperitoneal lymph nodes simultaneously with a cervical lymphadenopathy. The size of the lymph nodes varied between 5 mm to 32 mm. The subclassification showed the necrotizing type in 14 patients, in one there was a predominant xanthomatous tissue reaction around the necrotic areas (xanthomatous type), and in 4 patients the disease was recognized as the proliferative type without necrosis (in two with a variously intense apoptosis of the proliferating lymphocytes). Of 10 consult cases the tumor was primarily evaluated as B cell lymphoma not otherwise specified (1x), peripheral T cell lymphoma (1x), classical Hodgkin lymphoma of mixed cellularity (1x); two patients were submitted with a differential diagnosis between peripheral T cell lymphoma and HNL/K-F; in one diagnosis of probable EBV lymphadenitis and in one diagnosis HNL/K-F was made. There were no data submitted in the remaining three cases. The authors stress diagnostic features which should lead to the diagnosis of the disease and should prevent unnecessary oncological staging investigations and potential chemotherapy for a lymphoma. Among diagnostic features of HNL/K-F identification of the proliferating cells - CD8 activated lymphocytes with apoptotic decay prevail, there are frequent plasmacytoid monocytes and a striking reaction of macrophages which are CD68/myeloperoxidase positive. There are virtually no neutrophil granulocytes and there is a miminal participation of plasma cells. In case of necrotizing and xanthomatous type infectious causes are to be ruled out as well. In case we still need to distinguish HNL/K-F from a lymphoma PCR analysis of a rearrangement of the immunoreceptor gene in T cell population should be investigated.
Collapse
Affiliation(s)
- R Kodet
- Ústav patologie a molekulární medicíny, 2. LF UK a FN Motol, Praha.
| | | | | | | | | | | |
Collapse
|
31
|
Kamarádova K, Campr V, Kalinová M. [What is your diagnosis? Follicular lymphoma, eliminating systemic disease but considering a diagnosis of primary cutaneous lymphoma with follicular cells]. Cesk Patol 2012; 48:207-209. [PMID: 24044134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|
32
|
Kamarádová K, Campr V, Kalinová M. [What is your diagnosis? Primary cutaneous lymphoma with marginal zone cells]. Cesk Patol 2012; 48:207-208. [PMID: 24044130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|
33
|
Penka M, Schwarz J, Campr V, Pospíšilová D, Křen L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulíček P, Jonášová A, Kissová J, Kořístek Z, Schützová M, Vonke I, Walterová L. [Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ]. Vnitr Lek 2012; 58:163-168. [PMID: 22463098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Affiliation(s)
- M Penka
- Oddĕlení Klinické Hematologie FN Brno, Prednosta prof. MUDr. Miroslav Penka, CSc.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Campr V. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview]. Cesk Patol 2011; 47:84-93. [PMID: 21887923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A histological picture in pretreatment bone marrow trephine biopsy is an essential part of Ph-negative myeloproliferative neoplasm diagnosis according to WHO classification. Polycythaemia vera is histologically defined as a hypercellular trilinear myeloproliferation. Hypercellular haematopoiesis with granulocytic and megakaryocytic proliferation is typical for primary myelofibrosis. In essential thrombocythaemia the haematopoiesis is normocellular with proliferation of megakaryocytes only. The most important differential diagnostic features are morphology and distribution of megakaryocytes, and presence of fibrosis. In primary myelofibrosis there are typically ,dysplastic" megakaryocytes forming tight (dense) clusters, and variable extent of fibrosis, while mature megakaryocytes forming loose clusters and no fibrosis are found in essential thrombocythaemia. In reactive thrombocytosis and erythrocytosis the number of normally appearing megakaryocytes is not increased and they are not forming clusters. Prodromal (latent) phases of myeloproliferative neoplasms often unrecognized by recent WHO classification criteria are discussed as well as a differential diagnosis of myeloproliferative disorders associated with thrombocytosis.
Collapse
Affiliation(s)
- V Campr
- Ustav potologie a molekulární mediciny 2. LF UK a FN Motol, Praha.
| |
Collapse
|
35
|
Baumann I, Niemeyer C, Führer M, Behrendt S, Campr V, Csomor J, Furlan I, de Haas V, Kerndrup G, Leguit R, De Paepe P, Noellke P, Schwarz S. 378 Morphological differentiation of hypocellular refractory cytopenia of childhood and severe aplastic anemia and clinical outcome. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70380-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
36
|
Baumann I, Niemeyer C, Ftihrer M, Behrendt S, Campr V, Csomor J, Furlan I, de Haas V, Kerndrup G, Leguit R, De Paepe P, Noellke P, Schwarz S. 2 Morphological differentiation of hypocellular refractory cytopenia of childhood and severe aplastic anemia and clinical outcome. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70004-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]. Vnitr Lek 2011; 57:189-213. [PMID: 21416861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
In 2009, the recommendations of the Czech Collaborative Group for Ph- Myeloproliferative Diseases (CZEMP) for diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases (MPD), i.e., essential thrombocythemia (ET), polycythaemia vera (PV) and primary myelofibrosis (PMF) were updated and extended. The present article gives the rationale of the recommendations in full detail. The CZEMP diagnostic criteria for ET and PMF are based on histopathological (HP) findings, which must unconditionally be in line with the given clinical and laboratory characteristics of ET or of a certain stage of PMF, respectively. The platelet count is not decisive for diagnosis. In cases lacking an adequately taken and read HP finding, the Polycythemia Vera Study Group (PVSG) criteria are recommended. The diagnosis of typical PV is based on demonstration of the V617F mutation of the JAK2 gene along with a significant increase of red cell parameters. If these are close to borderline, the demonstration of increased total red cell mass (RCM) is required. In atypical cases lacking polyglobulia or elevated RCM, the HP picture of PV (in accordance with WHO description) plus JAK2 V617F mutation is satisfactory for diagnosis, or, in cases lacking JAK2 V617F mutation, the HP picture of PV along with polyglobulia (or increased RCM) is sufficient. The treatment principles of ET and other MPDs with thrombocythemia (MPD-T; i.e., the early stages of PMF and PV) are identical. The patients are stratified by their thrombotic risk (preceding thrombosis, another thrombophilic state, jAK2 mutation), presence of disease symptoms (mainly microcirculatory), platelet count and age. Only patients up to 65 years lacking the above mentioned risks with a platelet count < 1000 x 10(9)/l are considered as low-risk and do not demand cytoreducing therapy. The others are high-risk ones and have an indication for thromboreduction. In patients older than 65 years, the potentially leukemogenic drug hydroxyurea (HU) may be used. In the younger ones, the choice is between anagrelide (ANG) or interferon-alpha (IFN). In high-risk patients, the treatment goal is to maintain platelet counts below 400, and in low-risk ones, below 600 x 10(9)/l. In PV, polycythemia itself is another thrombotic risk factor. The condition is treated by bloodletting or erythrocytaphereses. If hematocrit levels < or =45 are not achieved, cytoreductive therapy using HU in patients over 65 years, or IFN in younger individuals is required. All patients with thrombocythemia in PV are high-risk and have an indication for cytoreduction. Acetylsalicylic acid is given to all patients with MPD-T with platelets < 1000 x 10(9)/l (at higher counts, hemorrhage is imminent), and to all individuals with PV, unless contraindication is present. In case of platelet count normalization, it may be withdrawn in cases of low-risk ET or PMF, not in JAK2+ PV. The treatment of advanced stages of PMF is symptomatic, with substitution of blood derivatives being the basis. The only curative treatment is allogeneic stem cell transplantation, which should not be indicated too early seeing to its risks, but also not too late--we must not allow transition into acute leukemia, which is heralded by blasts in the blood picture. The indication is the presence of any of the following criteria: values of hemoglobin < 10 g/dl, WBC < 4 x 10(9)/l and platelets < 100 x 10(9)/l, any percentage of blasts or > or = 10% immature granulocytes in the differential picture, >1 erythroblast per 100 cells--all at repeated examinations within at least a 2-month interval, and in addition, rapid progression of hepato-/splenomegaly, presence of general symptoms of the disease, portal hypertension and extensive swellings.
Collapse
Affiliation(s)
- J Schwarz
- Klinický úsek Ustavu hematologie a krevní transfuze Praha.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Votavova H, Forsterova K, Campr V, Sritesky J, Velenska Z, Pytlik R, Kubackova K, Prochazka B, Kodet R, Spicka I, Krejcova H, Trneny M, Klener P. Distinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reaction. Neoplasma 2010; 57:449-54. [PMID: 20568899 DOI: 10.4149/neo_2010_05_449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Primary mediastinal B-cell lymphoma (PMBL) seems to be reliably distinguished from diffuse large B-cell lymphoma (DLBCL) with microarray technology. We measured expression of Fcer2, Pdl2 and Blk genes using real-time quantitative polymerase chain reaction (RTqPCR) on formalin fixed, paraffin embedded material (FFPE) and suggested a formula to discriminate PMBL from DLBCL. For 39/82 included patients the diagnosis of PMBL was expected clinico-pathologically. Diagnosis of 10/39 and 2/43 of clinically considered PMBLs and DLBCLs, respectively, was not genetically confirmed. Compared to confirmed PMBLs, unconfirmed ones showed clinical features similar to DLBCLs, e.g. spleen infiltration (p=0,028) and decreased invasiveness in pericardium (p=0,045). They tended to have more common infradiaphragmatic involvement, less often tumor sclerosis or fluidothorax. There were no immunohistochemical differences between genetically confirmed and unconfirmed PMBLs. New approach of distinguishing PMBL and DLBCL is presented. It is based on expression of three genes in routinely available FFPE material using RTqPCR.
Collapse
Affiliation(s)
- H Votavova
- Charles University, Prague, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Sýkorová A, Belada D, Smolej L, Pytlík R, Benesová K, Vásová I, Papajík T, Sálek D, Procházka V, Matuska M, Brejcha M, Kubácková K, Kabícková E, Móciková H, Campr V, Trnený M. [Staging of non-Hodgkin's lymphoma--recommendations of the Czech Lymphoma Study Group]. Klin Onkol 2010; 23:146-154. [PMID: 20608324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
BACKGROUNDS The Ann Arbor system is typically used for the staging of Non-Hodgkin's lymphomas. This classification was nevertheless originally developed in the 1970s for Hodgkin's lymphoma, a disease usually confined to the lymph nodes with less frequent dissemination to extralymphatic organs/tissues and extremely rare primary extranodal involvement. Non-Hodgkin's lymphomas, however, are more often associated with extralymphatic involvement and primary extranodal lymphomas are relatively common (approximately 1/3 of cases). Therefore, the value of the Ann Arbor staging system appears to be limited in these cases. An analysis of data from centres participating within the Czech Lymphoma Study Group showed that staging of Non-Hodgkin's lymphomas with extranodal involvement is not uniform. DESIGN At the end of 2009, a draft for a Non-Hodgkin's lymphomas staging system was put forward for use by the lymphoma register of the Czech Lymphoma Study Group with special regard paid to the involvement of extralymphatic organs/tissues. This draft was further refined following comments from members of the Czech Lymphoma Study Group committee and the final form was accepted at the meeting of the Czech Lymphoma Study Group committee in January 2010. RESULTS A consensus was reached at the meeting of the Czech Lymphoma Study Group committee regarding the staging of various combinations of nodal and extranodal involvement. For the purpose of suitable staging and appropriate treatment intensity, extranodal organs were divided into "major"--liver, lungs, bones, mesothelium (pleura, peritoneum, pericardium) and soft tissues. All other organs were defined as "minor". CONCLUSION The Ann Arbor staging system is suitable for the staging of Non-Hodgkin's lymphomas with lymph node/lymphatic tissue involvement. As regards the extralymphatic spread of the disease or primary extranodal lymphomas, this classification should rather be adapted to practical needs. The validity of the updated classification system will be assessed in both prospective and retrospective Czech Lymphoma Study Group studies.
Collapse
Affiliation(s)
- A Sýkorová
- Oddelení klinické hematologie, II. interní klinika FN HK a LF UK, Hradec Králové.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Campr V. [Personalized medicine in haematooncology--the pathologist's perspective]. Cas Lek Cesk 2010; 149:464-467. [PMID: 21121135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The concept of personalized medicine is not only an individualized therapeutic management of a patient; its prerequisite is an individualized approach to diagnosis. Most of oncological diagnoses and a many prognostic features are provided by a pathologists. The pathologist uses not only basic histological methods, but also a morphoproteomic and morphogenomic approaches. Integral part of a contemporary oncological diagnosis is a molecular investigation of a tumour, which can both prove the presence of molecules suitable for targeted therapy, and design a molecular "patient-specific" marker for minimal residual disease monitoring.
Collapse
Affiliation(s)
- Vít Campr
- Univerzita Karlova v Praze, 2, lékarská fakulta, Ustav patologie a molekulární medicíny Motol, Praha.
| |
Collapse
|
41
|
Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulícek P, Campr V, Kren L, Penka M. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia. Semin Thromb Hemost 2006; 32:231-45. [PMID: 16673277 DOI: 10.1055/s-2006-939434] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The rationale of the Czech Hematological Society guidelines for diagnosis and treatment of Philadelphia chromosome-negative myeloproliferative disorders with thrombocythemia (MPD-T) is reviewed. For diagnosis of MPD-T, the classification according to the World Health Organization or to the Rotterdam criteria is preferred because they distinguish true essential thrombocythemia from prefibrotic or early fibrotic idiopathic myelofibrosis and prepolycythemic polycythemia vera. The histopathology-based nosological distinction provided by these classifications yields valuable information on prognosis (including the risks of transition into secondary acute myeloid leukemia and myelofibrosis). Another serious complication in MPD-T is thrombosis (arterial or venous), the main risk factors of which are age, previous thrombosis, platelet counts 350 to 2,200 x 10 (9)/L (peak at approximately 900 x 10 (9)/L) and the presence of additional thrombophilic risk factors (hereditary thrombophilia, any hypercoagulable state, cardiovascular disease). The hemorrhagic risk starts increasing progressively at platelet counts > 1,000 x 10 (9)/L. Treatment should be stratified with respect to the thrombotic and hemorrhagic risks. In high-risk patients, thromboreductive therapy is warranted. All of the cytostatic drugs, including hydroxyurea, may be leukemogenic and should be given only to patients > 60 years old, whereas anagrelide or interferon alpha are preferred in younger individuals. In low-risk patients, antiaggregation therapy is sufficient, unless the platelet count exceeds 1,000 x 10 (9)/L, which is another indication for thromboreduction. Thrombopheresis is indicated in thrombocythemia > 2,000 x 10 (9)/L.
Collapse
Affiliation(s)
- Jirí Schwarz
- Clinical Section, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Schwarz J, Mikulenková D, Cermáková M, Polanská V, Michalová K, Marinov I, Campr V, Ransdorfová S, Marková J, Pavlistová L, Brezinová J, Sajdová J, Sponerová D, Volková Z, Benesová K, Cermák J, Vítek A, Cetkovský P. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers. Neoplasma 2006; 53:219-25. [PMID: 16652191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Morphological examination is the routine first step in the diagnosis of hematological malignancies, including chronic lymphocytic leukemia (CLL). Atypical cell morphology according to the FAB criteria is known to herald disease progression. Several years ago, it was proposed that FAB morphology at diagnosis had a considerable prognostic impact. However, this proposal has not been widely adopted in practice. Thus we questioned the prognostic value of the morphological examination, which was performed retrospectively in 88 patients out of our 110 institutional registry patients (70 males and 40 females, median age 57 yrs) with CLL at diagnosis. We related the results to the more modern prognostic markers. Atypical FAB morphology was shown to correlate with IgVH gene mutation status, trisomy of chromosome 12 and deletion of 17p detected either by conventional G-banding or by fluorescence in situ hybridization (FISH) analysis. The correlation of FAB morphology with CD38 antigen expression or with the histopathological pattern of bone marrow infiltration was not significant. Overall survival (OS) data were available for 84 morphologically examined patients. The patients with atypical morphology (64 patients) had a significantly shorter OS (103 months) than the 20 patients presenting with typical CLL morphology (237 months; p=0.03). Only the mutation status of IgVH genes correlated more closely with OS (p=0.002). Of note, there was no leukemia-related death within "unmutated" cases who had typical FAB morphology (p=0.14), and vice versa, the mutation status had a significant prognostic impact within the morphologically atypical cases (p=0.01). Thus FAB morphology and the mutation status may yield complementary prognostic information. OS was affected both by the presence of cytogenetic aberrations (p=0.03) - most adversely by deletions of 17p and 11q, and by CD38 expression (p=0.003). We conclude that careful examination of peripheral blood smears according to FAB is a simple, cheap and valuable tool in the first-line assessment of prognosis of CLL patients and should not be overlooked even in 3rd millennium when more sophisticated prognostic markers are at hand. This ought to be confirmed in larger prospective studies with multivariate analysis of data.
Collapse
MESH Headings
- ADP-ribosyl Cyclase 1/analysis
- Adult
- Aged
- Aged, 80 and over
- Female
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Variable Region/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukocyte Count
- Male
- Middle Aged
- Mutation
- Prognosis
Collapse
Affiliation(s)
- J Schwarz
- Institute of Hematology and Blood Transfusion, CZ-128 Prague, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Olejárová M, Campr V, Pavelka K. [Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis). Case study and a literature review]. Vnitr Lek 2004; 50:786-92. [PMID: 15633936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
Kikuchi-Fujimoto disease is a rare feverish disease characterised by lymphadenopathy, the most frequently cervical, exanthem, arthralgias and arthritis. It affects especially young women. Patients have high erythrocyte sedimentation rate (ES) and leucopenia, antibodies are missing. Course of the disease is usually very benign and can subside spontaneously. However, clinical picture is usually very dramatic and can suggest infectious, autoimmune or malign systemic disease; also association with some of autoimmune diseases was described. Its occurrence is sporadic in all the world, the most of cases were seen in Asia, in the Czech Republic it has not been yet described. Therapy consists in antibiotics administration followed with corticoid therapy and usually can restore patients to perfect health. However, exacerbations have also been described. We describe a case of a 60 year old man, a past top sportsman, who has never been seriously ill except sport traumas and prosthesis implantation for coxarthritis reasons. The last two years he has suffered from exanthem and leucopenia of an unclear origin. In May 2002 he become feverish and arthritis, lymphadenopathy, splenomegalia and exanthem progression, high ES rate and high serum level of C-reactive protein (CRP) appeared in him. His condition was first evaluated as septic condition (founded staphylococci in two blood cultures), however, cause of potential sepsis has not been identified. The patient was treated with antibiotics with improvement of his total health condition after second treatment regiment. A neck node biopsy was done because of suspicion on lymphoprolipherative disease and histiocytic necrotizing lymphadenitis of Kikuchi type was found. Autoantibodies assessment was completely negative. After antibiotic and corticoid therapies his clinical condition quite quickly standardized and ES rate and serum CPR level decreased. 4 month after lowering the dose of prednisolon a temporary exacerbation of the disease appeared and again disappeared after increasing the dose of corticoid.
Collapse
|
44
|
Abstract
Myoblastic myoma was first described in 1926. Immunohistochemical methods have proven the neuroectodermal origin of this tumour. It most frequently affects individuals between 30 and 60 years of age, with a significant female predominance. In most cases it is a benign solitary tumour, with multiple lesions found in 25% of cases. The malignant variant of the tumour is diagnosed in less than 3% of cases. This case report of a 30-year-old woman describes the appearance of a solid resistance between her breasts following delivery of her child, with similar findings on the neck and wrists. Histopathological examination confirmed the presence of a benign variant of myoblastic myoma.
Collapse
Affiliation(s)
- G Janousková
- Department of Dermatology and Venereology, the 2nd Medical School of Charles University and University Hospital Motol, Prague 5, V Uvalu 84, Czech Republic.
| | | | | | | | | | | |
Collapse
|
45
|
Soukup J, Krsková L, Campr V. [New aspects of MALT lymphomas of the stomach]. Cesk Patol 2003; 39:120-5. [PMID: 14631809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
The knowledge about MALT lymphomas has dramatically changed in the last few years. The genesis of MALT lymphomas has become clearer, and new tools in modern diagnostics are available. This article, as a concise review, summarises the latest data and the clinical and morphological characteristics with the aspect of routine diagnostics. The characteristic translocation t(11;18) and its chimeric transcript API2-MALT1 with antiapoptotic function is emphasised.
Collapse
Affiliation(s)
- J Soukup
- Ustav patologie a molekulární medicíny 2. LF UK a FN Motol, Praha
| | | | | |
Collapse
|
46
|
Kodet R, Mrhalová M, Krsková L, Soukup J, Campr V, Neskudla T, Szépe P, Plank L. Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization. Virchows Arch 2003; 442:538-47. [PMID: 12728315 DOI: 10.1007/s00428-003-0809-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2002] [Accepted: 02/11/2003] [Indexed: 01/08/2023]
Abstract
INTRODUCTION Mantle cell lymphoma (MCL) is a clinicopathological entity characterized by an aggressive clinical course, morphological features, and overexpression of cyclin D1 due to juxtaposition of the bcl-1 locus (and CCND1 gene coding for the cyclin D1) to the IgH gene. This phenomenon is caused by t(11;14)(q13;q32). The morphological diagnosis of MCL may pose difficulties. Ancillary methods are available to support the diagnosis. PATIENTS AND METHODS We studied a group of 32 patients with MCL; 24 men and 8 women. The median age at the diagnosis was 64 years. We characterized the investigated group by histology, and to analyze the immunohistochemical (IHC) profile we used a panel of antibodies including anti-cyclin D1. Polymerase chain reaction (PCR) was used to detect the rearrangement of bcl-1/IgH in 26 cases (in 11 patients, the DNA was isolated from frozen tissues or from nucleated cells of bone-marrow aspirate or peripheral blood, in 15 patients we utilized paraffin-embedded material). Dual color fluorescence in situ hybridization (FISH) on interphase nuclei detecting the t(11;14)(q13;q32) was applied in all 32 cases. RESULTS Cyclin D1 IHC was positive in 29 of 30 cases tested (97%). In six, the result was weak and difficult to rely on to support the diagnosis. PCR revealed the fusion gene in 14 of the 26 cases (54%). The best yield was obtained from fresh and frozen samples (8 of 11 positive). Using FISH, we identified the translocation in all 32 patients, the findings being easily interpretable in 29 patients. In three cases, the intensity of red and green signals was weaker and difficult to read though the co-hybridized signals were identified. The classical pattern of the translocation was observed in 26 patients, while in 3 we found variant patterns suggesting a loss of the V segment of the IgH gene (2x) and a shift in the breakpoint region at chromosome 11 (1x). CONCLUSION The diagnosis of MCL should be supported by a complex laboratory approach. Interphase FISH seems a useful complementary method to morphology and IHC. It is applicable to various tissues and cells prepared as tissue imprints or histological sections.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/analysis
- Chromosomes, Human, Pair 11
- Chromosomes, Human, Pair 14
- Cyclin D1/analysis
- DNA, Neoplasm/analysis
- Female
- Fluorescent Antibody Technique, Indirect
- Humans
- In Situ Hybridization, Fluorescence
- Lymphoma, Mantle-Cell/chemistry
- Lymphoma, Mantle-Cell/diagnosis
- Lymphoma, Mantle-Cell/genetics
- Male
- Middle Aged
- Polymerase Chain Reaction
- Retrospective Studies
- Translocation, Genetic
Collapse
Affiliation(s)
- Roman Kodet
- Department of Pathology and Molecular Medicine, Charles University, 2nd Medical School and Faculty Hospital in Motol, V Uvalu 84, 150 06, Prague 5-Motol, Czech Republic.
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Soukup J, Krsková L, Mrhalová M, Kodet R, Campr V, Kubácková K, Trnĕný M. [Large-cell diffuse B-cell lymphoma: heterogenous origin and prognosis from the aspect of modern diagnosis]. Cas Lek Cesk 2003; 142:417-22. [PMID: 14515445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
BACKGROUND Diffuse large B-cell lymphomas represent a heterogeneous group of tumors with a different origin, morphological findings and a variable clinical prognosis. These tumors have been recently classified into two prognostically relevant subgroups differing in the gene expression. The key genes suitable for routine diagnostics of DLBCL have not been yet identified. The aim of this work was to study changes and expression of several genes and proteins participating in the genesis of DLBCL. METHODS AND RESULTS We analysed a group of 31 patients with diffuse large B-cell lymphomas. Basic clinical data including follow-up of the patients were available. Tumors were examined by a panel of immunohistochemical reactions with antibodies against CD20, CD79a, BCL-2, BCL-6, CD10, Ki-67 and TP53. FISH was used to detect a translocation t(14;18)(q32;q21) and/or a break in BCL6 region (3q27) suggestive of a translocation with a variable translocation partner t(3;?). PCR was utilized to detect the translocation t(14;18) and a clonal rearrangement of heavy and/or kappa chain of the immunoglobin genes. CONCLUSIONS The expression of BCL-2 protein appeared to correlate with a higher mortality rate. The expression of other proteins examined in the study did not correspond significantly with the clinical development of the disease. Tumors with follicular lymphoma as a component had significantly higher mortality rate than the tumors developing de novo. Moreover, higher mortality was evident in cases with higher values of the International Prognostic Index (IPI).
Collapse
MESH Headings
- DNA-Binding Proteins/analysis
- DNA-Binding Proteins/genetics
- Humans
- Immunohistochemistry
- Lymphoma, B-Cell/diagnosis
- Lymphoma, B-Cell/genetics
- Lymphoma, Large B-Cell, Diffuse/chemistry
- Lymphoma, Large B-Cell, Diffuse/diagnosis
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/mortality
- Neprilysin/analysis
- Prognosis
- Proto-Oncogene Proteins/analysis
- Proto-Oncogene Proteins/genetics
- Proto-Oncogene Proteins c-bcl-6
- Survival Rate
- Transcription Factors/analysis
- Transcription Factors/genetics
- Translocation, Genetic
Collapse
Affiliation(s)
- J Soukup
- Ustav patologie a molekulární medicíny 2. LF UK a FNM, Praha.
| | | | | | | | | | | | | |
Collapse
|
48
|
Mand'áková P, Campr V, Kodet R. [Correlation of results of flow cytometry and morphologic findings in the diagnosis of malignant B-cell lymphoma]. Cas Lek Cesk 2003; 142:651-5. [PMID: 14689823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
BACKGROUND Immunophenotyping of malignant lymphomas becomes necessary for the correct classification, for the design of therapy and for prognosis projection (WHO). Although the spectrum of classic immunohistochemical (IHC) examinations in paraffin embedded or frozen sections has recently considerably extended, IHC should preferably be combined with flow cytometry. The main advantage of flow cytometry is a synchronous application of two or more antibodies marked with various fluorochromes in one sample. The method is limited by utilizing native material only. METHODS AND RESULTS The flow cytometry combined with histological and IHC investigations were used in diagnosis of primary non-Hodgkin's lymphomas of B-cell origin (B-NHL) and for bone marrow staging or restaging. We studied 90 patients with confirmed or suspected B-NHL and we found a good correlation in 89% of samples of primary lymphomas and in 85% of bone marrow samples when IHC and flow cytometry results were compared. The overall efficacy of the flow cytometry determination in lymphoma infiltration of the samples was 89%. CONCLUSIONS Immunophenotyping utilizing flow cytometry contributes to diagnosis and classification of B-cell lymphomas in the significant proportion of investigated patients. In some cases it is even unnecessary to employ IHC examination of tissue sections. The method is especially suitable for determination of monoclonal populations of B-cells by detection of cell surface markers because it is more specific and sensitive than IHC. The immunophenotyping by flow cytometry as an auxiliary method and in correlation with morphological findings it can make the diagnosis of B-cell lymphomas faster and more specific.
Collapse
Affiliation(s)
- P Mand'áková
- Ustav patologie a molekulární medicíny 2. LF UK a FNM, Praha.
| | | | | |
Collapse
|
49
|
Campr V, Benesová E, Kolárová M. [Comparison of proliferative activity in malignant lymphomas determined by immunohistologic methods with various antibodies]. Cesk Patol 1997; 33:43-45. [PMID: 9340213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Proliferation Index (PI) was evaluated in a group of 48 malignant lymphomas. Comparison of 3 antibodies showed that DAKO-EPOS Anti-PCNA/HRP and MIB-1 (Immunotech) suite to routine PI evaluation. Low figures of PI were obtained when using DAKO-EPOS Anti-Ki-67/HRP which did not even discriminate between prognostic groups of malignant lymphomas.
Collapse
Affiliation(s)
- V Campr
- Hlavův I. pathologickoanatomický ústav VFN a 1. LF UK, Praha
| | | | | |
Collapse
|
50
|
Sváb J, Campr V. [Extraskeletal mesenchymal chondrosarcoma]. Rozhl Chir 1996; 75:213-5. [PMID: 8768996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- J Sváb
- I. chirurgická klinika 1. LF UK a VFN, Praha
| | | |
Collapse
|